Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22547844 | 0.80 | IRAK4 (0.46) | IRAK4ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL27790246 | 0.80 | ADORA2A (0.53) | IRAK4ADORA2AADORA1DGAT1ADORA2B | |
| SCHEMBL130754 | 0.77 | KDR (0.44) | IRAK4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30051491 | 0.77 | KDR (0.44) | IRAK4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20665062 | 0.76 | IRAK4 (0.37) | IRAK4 | |
| SCHEMBL2749179 | 0.76 | TLR7 (0.40) | IRAK4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4266131 | 0.75 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DDYRK1A | |
| SCHEMBL30677346 | 0.74 | IRAK4 (0.33) | IRAK4PDE4BDYRK1ACDK1 | |
| SCHEMBL4086353 | 0.74 | SLC22A12 (0.42) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL4261603 | 0.73 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792264-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2024-01-03 | — | — | EP | disclosed |
| CN-108368114-B | Pyrrolopyrimidine compounds as MNK inhibitors | 生命弧度公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3792264-A1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LifeArc (GB) | 2021-03-17 | — | — | EP | disclosed |
| EP-3377494-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2021-03-03 | — | — | EP | disclosed |
| EP-3377494-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2021-03-03 | — | — | EP | disclosed |
| US-10604524-B2 | Pyrropyrimidine compounds as MNKs inhibitors | LIFE ARC (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20180346469-A1 | Pyrropyrimidine Compounds As MNKS Inhibitors | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2018-12-06 | — | — | US | disclosed |
| EP-3377494-A1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LifeArc (GB) | 2018-09-26 | — | — | EP | disclosed |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101611041-A | Condensed heterocyclic compouds | TAKEDA PHARMACEUTICAL (JP) | 2009-12-23 | — | — | CN | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1904498-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007004749-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346469-A1 | Pyrropyrimidine Compounds As MNKS Inhibitors | NR0B1, NR4A1, NR2E1 | IRAK4 1151/4885PDE4A 4155/4885PDE4B 4355/4885 |
| US-10604524-B2 | Pyrropyrimidine compounds as MNKs inhibitors | NR0B1, NR2E1, HRH4 | IRAK4 1181/4885PDE4A 4259/4885PDE4B 4455/4885 |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | IRAK4 868/4885PDE4A 3868/4885PDE4B 3507/4885 |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | IRAK4 2370/4885PDE4A 4076/4885PDE4B 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.